Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Kadmon Corporation, LLC Clear all
Completed Phase 1 Interventional

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

NCT00086528
View directory record Official record
Conditions
Cancer
Interventions
XL647
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Stanford, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 5, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

NCT03096080
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Recessive
Interventions
Tesevatinib
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
5 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 5, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Study of XL647 in Subjects With Non-Small-Cell Lung Cancer

NCT00364780
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
XL647
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
7
States / cities
Port Saint Lucie, Florida • Chicago, Illinois • Urbana, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 5, 2026, 5:30 AM EDT
Terminated Phase 3 Interventional

KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy

NCT01487174
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
KD019, Erlotinib
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
New Haven, Connecticut • Farmington, New Mexico
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 5, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

NCT00522145
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
XL647
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Gilroy, California • Sacramento, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 5, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis

NCT02688647
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Belumosudil, BSC
Drug · Other
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 5, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy

NCT02317627
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
KD025
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Glendale, Arizona • Santa Ana, California • Lake Charles, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 5, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

NCT02844439
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Brain Tumor
Interventions
Tesevatinib
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Tucson, Arizona • Duarte, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 5, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT00730158
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
KD018, Irinotecan, Placebo
Drug
Lead sponsor
Edward Chu, MD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
New Haven, Connecticut • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 5, 2026, 5:30 AM EDT
Terminated Phase 4 Interventional

Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin

NCT00456248
View directory record Official record
Conditions
Hepatitis C
Interventions
Infergen and ribavirin
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Atlanta, Georgia • New Orleans, Louisiana • Harrisburg, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 5, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris

NCT02106195
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
Belumosudil
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 5, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

NCT02616393
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Leptomeningeal Metastases, Brain Metastases
Interventions
Tesevatinib
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Beverly Hills, California • Newport Beach, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 5, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

NCT02852967
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Belumosudil, Placebo
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
14
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 5, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

NCT02616055
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
tesevatinib
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 62 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 5, 2026, 5:30 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

NCT02154529
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain
Interventions
Tesevatinib, Trastuzumab
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
La Jolla, California • Indianapolis, Indiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 5, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

NCT00336765
View directory record Official record
Conditions
Cancer
Interventions
XL647
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Stanford, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 5, 2026, 5:30 AM EDT